DAPIXA: Dapagliflozin 5mg, 10mg Tablet
DAPIXA M: Dapagliflozin 5mg, 10mg Tablet+Metformin 500mg Tablet
DAPIXA DM: Dapagliflozin 5mg, 10mg Tablet+Metformin 1000mg Tablet
DAPIXA: Dapagliflozin 5mg, 10mg Tablet
DAPIXA M: Dapagliflozin 5mg, 10mg Tablet+Metformin 500mg Tablet
DAPIXA DM: Dapagliflozin 5mg, 10mg Tablet+Metformin 1000mg Tablet
as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
How it works
Sodium-glucose cotransporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.
Metformin: Helps decrease hepatic (liver) glucose production, to decrease GI glucose absorption and to increase target cell insulin sensitivity. Also used as an adjunct to DPP-4 inhibitors, diet, exercise and lifestyle changes such as weight loss to improve glycemic (blood sugar) control in adults with type 2 diabetes
Indications
as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Dosage
The recommended starting dose is 5 mg once daily, taken in the morning, with or without food.
Dose can be increased to 10 mg once daily in patients who require additional glycemic control.
Assess renal function before initiating Dapagliflozin. Do not initiate if eGFR is below 60 mL/min/1.73 m2
Discontinue if eGFR falls persistently below 60 mL/min/1.73 m2
Side Effects
Female genital mycotic infections, nasopharyngitis, and urinary tract infections
Contraindication
History of serious hypersensitivity reaction to Dapagliflozin.
Severe renal impairment, end-stage renal disease, or dialysis.
Copyright © 2020 tasmed
.png)
